Research Paper Volume 14, Issue 6 pp 2868—2879
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
Figure 3. Associations of overall survival and TP53 and BRAF mutation types with tumor-infiltrating immune cells. (A, B) Patients with low tumor-infiltrating CD8+ T cells/activated NK cells had shorter OS than patients with high tumor-infiltrating CD8+ T cells/activated NK cells. (C, D) Patients with low tumor-infiltrating regulatory T cells /activated myeloid dendritic cells had shorter OS than patients with high regulatory T cells /activated myeloid dendritic cells. (E–H) The level of tumor infiltrating CD8+ T cells was correlated with the mutation of TP53/BRAF. Data was from TCGA database.